Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

Fig. 4

HuNb1-IgG4 shows low affinity to human RBCs and high safety in cynomolgus monkeys. a The activity of HuNb1-IgG4 and Hu5F9-G4 binding to RBCs isolated form fresh blood of six people. The binding activity was detected by FACS. The binding activity detections from two people were shown. The result from other four people were displayed in Additional file 3. b The effect of HuNb1-IgG4 on RBC agglutination, with Hu5F9-G4 and H6B12 as controls. The experiment was performed in triplicate and one representative experiment was shown. c, d The HGB levels (c) and RBC counts (d) in two individual cynomolgus monkeys administrated with a single intravenous infusion of HuNb1-IgG4 at the doses of 10Ā mg/kg or 30Ā mg/kg. e, f The HGB levels (e) and RBC counts (f) in two individual cynomolgus monkeys administrated with a priming dose of 3Ā mg/kg followed by another dose of 60Ā mg/kg or 200Ā mg/kg respectively. The above monkey experiments were performed once

Back to article page